Kineta, Inc/de Form 4 insider transactions

Kineta, Inc.'s Chief Scientific Officer, Thierry Guillaudeux, has reported the disposition of all his common stock and stock options in Kineta following the company's merger with TuHURA Biosciences, Inc.

A Kineta, Inc. director has reported the disposition of all direct and indirect common stock and stock options, effective June 30, 2025, as a result of the company's merger with TuHURA Biosciences, Inc.

Kineta, Inc.'s Chief Financial Officer, Keith Baker, has reported the complete disposition of his Kineta common stock and stock options as a result of the company's merger with TuHURA Biosciences, Inc.

A Kineta, Inc. director's common stock holdings were converted into TuHURA Biosciences, Inc. shares and stock options were canceled as a result of the recently completed merger between Kineta and TuHURA.

A recent SEC Form 4 filing reveals Kineta, Inc. director Marion R. Foote's disposition of common stock and cancellation of stock options as a result of the company's merger with TuHURA Biosciences, Inc.

Craig W. Philips, President and Secretary of Kineta, Inc., reported the disposition of all Kineta common stock and stock options as a result of Kineta's merger with TuHURA Biosciences, Inc., with Kineta shares converting into TuHURA common stock and certain options being canceled.

Kineta, Inc. Director Richard Peters has disposed of all his common stock and stock options in Kineta following the completion of the two-step merger with TuHURA Biosciences, Inc.

A director of Kineta, Inc. has reported the complete disposal of all direct and indirect beneficial ownership in Kineta common stock and stock options, effective June 30, 2025, as a direct consequence of Kineta's merger with TuHURA Biosciences, Inc.

Kineta, Inc. Director David Arkowitz has reported the disposition of all his common stock and the cancellation of stock options in Kineta following the completion of its merger with TuHURA Biosciences, Inc.

Kineta, Inc. Director Scott J. Dylla reported the disposition of 17,794 common shares and the cancellation of certain stock options, along with the vesting of others, as a result of Kineta's merger with TuHURA Biosciences, Inc.

Kineta, Inc. Director and 10% Owner Shawn Iadonato reported significant stock option exercises and related share transactions, increasing his direct beneficial ownership, in connection with the company's merger agreement with TuHURA Biosciences, Inc.

Kineta, Inc. Director Kimberlee C. Drapkin reported the exercise of stock options and acquisition of common stock, alongside a tax-related disposition, following the approval of the merger agreement with TuHURA Biosciences, Inc.

Kineta, Inc. Director Richard Peters reported an increase in his beneficial ownership of common stock following the exercise of stock options and a new acquisition, driven by the vesting of options tied to the company's merger agreement with TuHURA Biosciences.

Kineta, Inc. Director Marion R. Foote reported significant changes in her beneficial ownership, including option exercises and share acquisitions, following the approval of the merger agreement with TuHURA Biosciences, Inc.

Kineta, Inc. Director Scott J. Dylla reported the exercise of stock options and subsequent share transactions, including a tax-related disposition and a new acquisition, following the full vesting of options tied to the company's merger agreements.

Kineta, Inc. Director David Arkowitz reported the exercise of stock options and the acquisition of additional common stock, with options vesting fully due to a recent merger agreement and stockholder approval.

Kineta, Inc.'s President and Secretary, Craig W. Philips, reported the exercise of 225,000 stock options and the acquisition of additional common stock, alongside the full vesting of his options, following a recent merger agreement.

Kineta, Inc.'s Chief Scientific Officer, Thierry Guillaudeux, reported significant stock transactions, including the exercise of options and subsequent share dispositions, tied to the company's merger agreement with TuHURA Biosciences, Inc.

Kineta, Inc. Director Raymond J. Bartoszek has reported recent stock acquisitions, dispositions, and the full vesting of stock options following the company's merger agreement approval.

Kineta, Inc.'s Chief Financial Officer, Keith Baker, engaged in significant equity transactions, including option exercises and share acquisitions, following the stockholder approval of the merger agreement with TuHURA Biosciences, Inc.

TuHURA Biosciences and Kineta, Inc. stockholders have overwhelmingly approved all merger-related proposals, including an increase in TuHURA's authorized shares and reincorporation to Delaware, clearing a significant hurdle for the companies' anticipated merger.

Kineta, Inc. Director Marion R. Foote has reported the exercise of 8,158 warrants to acquire common stock at $0.14 per share, increasing her direct beneficial ownership to 151,362 shares, as part of a pre-planned Rule 10b5-1 transaction.

TuHURA Biosciences, Inc. has entered into a definitive securities purchase agreement for a private placement totaling approximately $12.6 million, alongside an additional $3.0 million from prior warrant exercises, to fund its strategic merger with Kineta, Inc. and advance its oncology pipeline.

TuHURA Biosciences, Inc. announced a definitive agreement for a $12.5 million private placement and an additional $3.0 million from warrant exercises, aimed at funding its Phase 3 trial, Kineta merger, and pipeline advancement.

TuHURA Biosciences announced its Q1 2025 financial results and provided a corporate update, highlighting the anticipated initiation of a Phase 3 trial for IFx-Hu2.0 and progress towards acquiring Kineta, Inc.

TuHURA Biosciences will present a company overview at the H.C. Wainwright BioConnect Conference, highlighting its Phase 3 program and the acquisition of Kineta, including its VISTA inhibiting monoclonal antibody program.

TuHURA Biosciences amends its merger agreement with Kineta, extending the end date to June 30, 2025, and finalizes a separation agreement with its former Chief Scientific Officer, Dennis Yamashita.

TuHURA Biosciences has commenced a Phase 1b/2a clinical trial to evaluate the safety and feasibility of IFx-Hu2.0 in combination with Keytruda for patients with metastatic Merkel Cell Carcinoma of Unknown Primary Origin.

TuHURA Biosciences and Kineta presented updated results from clinical trials of KVA12123 and IFx-Hu2.0, showing potential in treating advanced melanoma and other cancers after failure of anti-PD-1 therapy.

TuHURA Biosciences announces that abstracts highlighting Kineta Inc.'s KVA12123 antibody and Moffitt Cancer Center scientists' examination of IFx-Hu2.0 therapy mechanisms have been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025.